KrasG12D and p53 mutation cause primary intra-hepatic cholangiocarcinoma

• Published in: Cancer research (Chicago, Ill.) Ill.), 2012-01, Vol.72 (6), p.1557-1567
• Main Authors: O’Dell, Michael R., Huang, Jing-Li, Whitney-Miller, Christa L., Deshpande, Vikram, Rothberg, Paul, Grose, Valerie, Rossi, Randall M., Zhu, Andrew X., Land, Hartmut, Bardeesy, Nabeel, Hezel, Aram F.
• Format: Article
• Language: English
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.CAN-11-3596

Intrahepatic cholangiocarcinoma (IHCC) is a primary cancer of the liver with a rising incidence and poor prognosis. Preclinical studies of the etiology and treatment of this disease are hampered by the relatively small number of available IHCC cell lines or genetically faithful animal models. Here we report the development of a genetically engineered mouse model of IHCC that incorporates two of the most common mutations in human IHCC, activating mutations of Kras (Kras G12D ) and deletion of p53. Tissue-specific activation of Kras G12D alone resulted in the development of invasive IHCC with low penetrance and long latency. Latency was shortened by combining Kras G12D activation with heterozygous or homozygous deletion of p53 (mean survival of 56 weeks versus 19 weeks, respectively), which also resulted in widespread local and distant metastasis. Serial analysis showed that the murine models closely recapitulated the multistage histopathologic progression of the human disease, including the development of stroma-rich tumors and the pre-malignant biliary lesions, intraductal papillary biliary neoplasms (IPBN) and Von Meyenburg complexes (VMC; also known as biliary hamartomas). These findings establish a new genetically and histopathologically faithful model of IHCC and lend experimental support to the hypothesis that IPBN and VMC are precursors to invasive cancers.